Newborn Screening Expansion: Two Rare Diseases to be Added in 2027 for Enhanced Infant Protection

Starting in 2027, France's national newborn screening program will include two additional rare diseases, increasing the total number of conditions screened to 18 during the initial days of a baby’s life. This initiative is part of ongoing efforts to bolster pediatric prevention in the country, marking a significant advancement for infant health and providing reassurance to families, as the testing process will remain unchanged.

Expanding the Protective Shield of Newborn Screening

Many may recall the well-known heel prick test, where a few drops of blood are collected from a newborn's heel before leaving the hospital. Introduced in 1972 to detect a single condition, phenylketonuria, this screening program has evolved significantly over the decades. While it initially identified only six diseases in the early 2020s, it has gradually expanded to encompass sixteen conditions today. In 2027, the program will surpass 18 diseases with the addition of two new targeted screenings.

The primary aim of this systematic monitoring is to identify rare but serious disorders, often of genetic origin, as early as possible, even before symptoms appear. The earlier a condition is detected in a newborn, the more effective the medical intervention can be in preserving the child's health and development.

Early Intervention Prevents Serious Complications

The two new conditions selected by the Ministry of Health, following recommendations from the Haute Autorité de Santé (HAS), are biotinidase deficiency and galactosemia. These medical terms refer to enzymatic disorders that healthcare teams are now well-equipped to manage when identified promptly.

Biotinidase deficiency hinders the body’s ability to properly utilize biotin, a crucial vitamin B8 essential for bodily functions. Without treatment, this condition can lead to neurological, skin, or auditory issues within months. However, when detected at birth, daily administration of a simple oral vitamin supplement can completely prevent these complications.

Galactosemia, on the other hand, affects a baby’s ability to metabolize galactose, a sugar found in milk. Its impact on the liver or growth can manifest very quickly. Again, newborn screening allows for immediate dietary adjustments, ensuring the infant is protected from the outset.

Consistent Experience for Parents at Maternity Hospitals

Despite the expanded list of diseases being screened, parents will not experience any changes in their overall experience. The collection of blood samples on filter paper will continue to follow the same protocol, taking place within two to three days after birth. No additional steps or forms will be required from parents.

Health authorities have also planned to optimize the overall organization of the program. The HAS recommends that expectant parents receive initial information during third-trimester consultations to discuss the screening process calmly before delivery. Moreover, maternity hospitals will be required to send the blood samples to analysis laboratories within 24 hours, including weekends, to ensure prompt and reassuring results.